Clear Street’s SELLAS Life Sciences SLS Stock Holding History

Clear Street’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-500,000	Closed	-$1.89M	–	1159
2025 Q4	$1.89M	Buy	+500,000	New	+$972K	0.01%	223

Other funds holding SLS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Clear Street's SLS Position: Q1 2026 in Review

Clear Street sold out of SELLAS Life Sciences (SLS) in Q1 2026, closing a stake of 500,000 shares — an estimated $1.89M sold.

Clear Street first reported a position in SLS in Q4 2025 and held it in 1 quarter. The position peaked at $1.89M in Q4 2025. 160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.

Clear Street reported no remaining SELLAS Life Sciences position as of Q1 2026 after selling out during the quarter.
Clear Street sold 500,000 SELLAS Life Sciences shares in Q1 2026, an estimated $1.89M.
Clear Street first reported a position in SELLAS Life Sciences in Q4 2025 and held it in 1 quarter.
Clear Street's SELLAS Life Sciences position peaked at $1.89M in Q4 2025.
160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.

Based on Clear Street's 13F filing for Q1 2026, filed 15 May 2026.